The Role of HDAC3 in Cardiac Growth and Development

HDAC3 在心脏生长和发育中的作用

基本信息

  • 批准号:
    7143835
  • 负责人:
  • 金额:
    $ 7.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The process of cardiac development incorporates cell differentiation and proliferation, which lead to the formation of the mature heart. Abnormalities in cardiac development result in congenital heart diseases, which is the most frequent form of birth defects in humans. More specifically, disruption of pathways affecting cardiac growth could be the underlying etiology in a subset of children born with hypoplastic left or right heart. Understanding the myocardial-specific molecular mechanisms by which signaling pathways control proliferation during cardiogenesis is a central issue in cardiac development and disease. These pathways are complex, and in many cases implicate transcription factors and cell cycle regulators. Covalent chromatin modifications play a critical role in transcriptional regulation and cell cycle progression, and therefore are expected to affect theses processes in the heart as well. Of these modifications, acetylation by histone acetyltransferases (HATs) and its reversal by histone deacetylases (HDACs) have been most studied and appreciated as a key event in regulating these processes. Experimental data from the mouse and zebrafish models suggest that HDAC1, a class I HDAC family member, plays an important role in embryonic cardiac growth and development. However, the role of other class I HDACs in cardiac growth and development remains unknown. As an extension of the principal investigator's interest in embryonic myocardial growth and development, he initiated a comprehensive analysis of the role of class I HDACs other than HDAC1. Preliminary studies suggest an important role for HDAC3, a class I member, both in cardiac growth and in development. In this pilot study, the investigators propose experiments that will offer insights into the role of HDAC3 in embryonic cardiac growth and development. They will pursue two aims: Specific Aim 1 will determine the effect of hdac3 deficiency in the zebrafish embryonic heart. The investigators will address this question by generating hdac3-deficient zebrafish embryos by disrupting hdac3 function with morpholino antisense oligonucleotides and comparing them with hdac3 mutants. The hdac3 deficient embryos will be evaluated by morphological and functional analysis with particular emphasis on the heart. Heart characterization will be completed by assessment of differentiation by the use of molecular markers, cell count determination, apoptosis, and proliferation assays. Specific Aim 2 will determine what are the cardiac defects in the hdac3 deficient embryos due to the loss of hdac3 function within cardiomyocytes or due to effects upon cellular functions in other support tissues? The investigators will address this question by reciprocal cell transplantations between control and hdac3-deficient embryos. They will also use selected molecular markers to dissect extracardiac processes relevant to cardiac development that are potentially affected in the hdac3 deficient embryos.
描述(申请人提供):心脏的发育过程包括细胞分化和增殖,导致成熟心脏的形成。心脏发育异常导致先天性心脏病,这是人类最常见的出生缺陷形式。更具体地说,影响心脏生长的通路中断可能是先天性左心或右心发育不全儿童的潜在病因。了解心脏发生过程中信号通路控制增殖的心肌特异性分子机制是心脏发育和疾病的核心问题。这些途径是复杂的,在许多情况下涉及转录因子和细胞周期调节因子。共价染色质修饰在转录调控和细胞周期进程中起着关键作用,因此预计也会影响心脏的这些过程。在这些修饰中,组蛋白乙酰转移酶(HATs)的乙酰化和组蛋白去乙酰化酶(hdac)的逆转被研究得最多,并被认为是调节这些过程的关键事件。小鼠和斑马鱼模型的实验数据表明,HDAC家族I类成员HDAC1在胚胎心脏生长发育中起重要作用。然而,其他I类hdac在心脏生长发育中的作用尚不清楚。作为首席研究员对胚胎心肌生长和发育兴趣的延伸,他发起了对HDAC1以外的I类hdac的作用的全面分析。初步研究表明,HDAC3(一类成员)在心脏生长和发育中都起着重要作用。在这项初步研究中,研究人员提出了一些实验,以深入了解HDAC3在胚胎心脏生长和发育中的作用。他们将追求两个目标:特异性目标1将确定hdac3缺乏对斑马鱼胚胎心脏的影响。研究人员将通过用morpholino反义寡核苷酸破坏hdac3的功能,产生hdac3缺陷的斑马鱼胚胎,并将其与hdac3突变体进行比较,来解决这个问题。hdac3缺陷胚胎将通过形态学和功能分析进行评估,特别强调心脏。通过分子标记、细胞计数测定、细胞凋亡和增殖试验来评估心脏的分化,从而完成心脏的鉴定。特异性目标2将确定hdac3缺陷胚胎由于心肌细胞内hdac3功能的丧失或由于对其他支持组织细胞功能的影响而导致的心脏缺陷是什么?研究人员将通过对照和hdac3缺陷胚胎之间的相互细胞移植来解决这个问题。他们还将使用选定的分子标记来解剖与心脏发育相关的心外过程,这些过程在hdac3缺陷胚胎中可能受到影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lazaros K. Kochilas其他文献

Familial Pseudocoarctation of the Aorta
  • DOI:
    10.1007/s00246-011-9933-8
  • 发表时间:
    2011-02-25
  • 期刊:
  • 影响因子:
    1.400
  • 作者:
    Michael K. Atalay;Lazaros K. Kochilas
  • 通讯作者:
    Lazaros K. Kochilas

Lazaros K. Kochilas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lazaros K. Kochilas', 18)}}的其他基金

Long-term outcomes in patients with single ventricle physiology
单心室生理学患者的长期结果
  • 批准号:
    9883836
  • 财政年份:
    2019
  • 资助金额:
    $ 7.5万
  • 项目类别:
Long-term Outcomes after Interventions for Congenital Heart Disease
先天性心脏病干预后的长期结果
  • 批准号:
    10219333
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
Long-term Outcomes after Interventions for Congenital Heart Disease
先天性心脏病干预后的长期结果
  • 批准号:
    9981776
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
Long-term Outcomes after Interventions for Congenital Heart Disease
先天性心脏病干预后的长期结果
  • 批准号:
    10455498
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
All Cause Mortality 1-30 Years After Interventions for Congenital Heart Diseases
先天性心脏病干预后 1-30 年的全因死亡率
  • 批准号:
    8670521
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
All Cause Mortality 1-30 Years After Interventions for Congenital Heart Diseases
先天性心脏病干预后 1-30 年的全因死亡率
  • 批准号:
    9241438
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
All Cause Mortality 1-30 Years After Interventions for Congenital Heart Diseases
先天性心脏病干预后 1-30 年的全因死亡率
  • 批准号:
    9096979
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
COBRE: WI HOSP OF RI: P57KIP2 IN VENTRICULAR CARDIOMYOCYTE DIFFERENTIATION
COBRE:RI 的 WI HOSP:心室心肌细胞分化中的 P57KIP2
  • 批准号:
    7720720
  • 财政年份:
    2008
  • 资助金额:
    $ 7.5万
  • 项目类别:
COBRE: WI HOSP OF RI: P57KIP2 IN VENTRICULAR CARDIOMYOCYTE DIFFERENTIATION
COBRE:RI 的 WI HOSP:心室心肌细胞分化中的 P57KIP2
  • 批准号:
    7610523
  • 财政年份:
    2007
  • 资助金额:
    $ 7.5万
  • 项目类别:
COBRE: WI HOSP OF RI: P57KIP2 IN VENTRICULAR CARDIOMYOCYTE DIFFERENTIATION
COBRE:RI 的 WI HOSP:心室心肌细胞分化中的 P57KIP2
  • 批准号:
    7381990
  • 财政年份:
    2006
  • 资助金额:
    $ 7.5万
  • 项目类别:

相似海外基金

Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
  • 批准号:
    22K09003
  • 财政年份:
    2022
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
  • 批准号:
    21K07762
  • 财政年份:
    2021
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
  • 批准号:
    20K16927
  • 财政年份:
    2020
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
  • 批准号:
    20H00526
  • 财政年份:
    2020
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
  • 批准号:
    20K21245
  • 财政年份:
    2020
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
  • 批准号:
    G0900887/1
  • 财政年份:
    2011
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
  • 批准号:
    05558090
  • 财政年份:
    1993
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
  • 批准号:
    04453031
  • 财政年份:
    1992
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了